<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639600</url>
  </required_header>
  <id_info>
    <org_study_id>95/CHUG/10/C2</org_study_id>
    <nct_id>NCT00639600</nct_id>
  </id_info>
  <brief_title>Transplantation of Pancreatic Islets in Patients With Type 1 Diabetes Mellitus and Functional Kidney Graft</brief_title>
  <acronym>GRAGIL1</acronym>
  <official_title>Transplantation d'îlots pancréatiques allogéniques Adultes Pour le Traitement du diabète insulinodépendant. Etude GRAGIL 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project is supported by a multicentric network of collaborators whose goal is
      to assess the efficacy of transplanting allogenic pancreas islets to restore insulin
      secretion in patients with type 1, insulin-dependent diabetes mellitus with kidney
      transplantation and to improve their metabolic control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to demonstrate the beneficial effect of islet allotransplantation in
      patients with type 1 diabetes with no endogenous insulin secretion, and with a functional
      kidney graft. The other objectives are to evaluate the conditions for the efficacy of islet
      cell transplantation, to assess the improvement in quality of life and the cost of the islet
      cell transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    a new study has began recently
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of insulin-independence at 6 and 12 months after transplantation, duration of insulin-independence, survival curves</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance (Measurement of portal pressure during islet injection) Quality of life (Questionnaires SF-36 and DQOL at inclusion time, then every 6 months during their waiting period and then 6 months and 12 months after transplantation) Costs</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>human pancreatic islet transplantation</intervention_name>
    <description>human pancreatic islet transplantation</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus

          -  Disease duration &gt; 5 years

          -  ketose antecedents

          -  Basal and stimulated plasma C-&lt; 0.2 ng/ml,&lt;0.06 nmol/l (glycemia must be measured
             simultaneously_ 1.20 g/l or 6.6 mM, stimulation with glucagon IV 1 mg -Measured at à
             T0 and T 6 min)

          -  Established kidney graft ≥ 6 months

          -  Current creatinine clearance: ≥ 50 ml/min/1.73 m² and Proteinuria &lt; 0.5 g/24h

          -  HbA1C&lt; 12%

        Exclusion Criteria:

          -  Hemostasis problems

          -  Documented hepatic pathology

          -  Patient under 18 or over 65 year-old

          -  Women with body weight over 70 kg (tolerance of 2 kg between inclusion day and
             transplantation day) or BMI &gt; 26

          -  Men with body weight &gt; 75 kg (tolerance of 3 kg between inclusion day and
             transplantation day) or BMI &gt; 26

          -  insuline needs &gt; 0.7 U/kg/j or 50 U/j

          -  Serious life-threatening pathology

          -  untreated hyperlipidemia

          -  Hypersensitivity to drugs rapamycine-alike

          -  Liver disease (transaminases or total bilirubin ≥ 3N)

          -  Failure to communicate or cooperate with the investigator

        Exclusion criteria that are specific to the use of Rapamycine

          -  Hypercholesterolemia (&gt; 350mg/dl, 9,1 mmol/l) not controlled

          -  Hypertriglyceridemia (&gt; 500 mg/dl, 5,6 mmol/l) not controlled

          -  Leukocytes &gt; 4500 /mm3 , neutrophils &gt; 2000/ mm3, platelets &gt; 100000/ mm3

          -  Any clinical or biological pathology that could interfere with the study

          -  Past or present neoplasia (with the exception of non melanoma skin cancers)

          -  Any hemostasis disorder needing a prolonged treatment with anticoagulation drugs.
             Low-dose aspirin is permitted.

          -  Pregnancy, lactation, pregnancy project or absence of efficient contraception

          -  Any medical or psychosocial condition susceptible to interfere with the study, such as
             drug abuse or recent alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Y Benhamou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Grenoble, Department of Endocrinology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Strasbourg</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Surgery</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>May 28, 2010</last_update_submitted>
  <last_update_submitted_qc>May 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pierre-Yves Benhamou</name_title>
    <organization>University Hospital, Grenoble</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

